AVS began enrolling patients in October 2024 in the POWER PAD II U.S. IDE trial, which is a prospective, single-arm, multi-center study evaluating the technical and clinical success of the PULSE ...

BOSTON--(BUSINESS WIRE)--AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced today that it ...